文献速递乳腺癌放疗

三阴性淋巴结阴性乳腺癌的乳房切除术后放射治疗

Postmastectomy radiation therapy for triple negative, node-negative breast cancer.
PubMed 文献 · Radiother Oncol · 2018-12-20

基于美国国家癌症数据库(2004-2014年)纳入14,464例非转移性三阴性乳腺癌(TNBC)pT1-4N0M0期行乳房切除术的女性患者,评估乳房切除术后放射治疗(PMRT)的使用模式及对总生存(OS)的影响。结果显示PMRT使用率为10.8%,pT3期患者PMRT与更优OS相关,而其他T分期未见获益;作者建议进一步前瞻性研究以明确PMRT在淋巴结阴性TNBC中的获益。

要点

  • 14,464例淋巴结阴性TNBC患者中仅10.8%接受PMRT,T1期仅5.7%,T3期达51.6%。
  • PMRT与pT3期患者更优OS相关,但在其他T分期患者中未见获益。
  • 年龄较大与PMRT使用可能性降低相关,T分期升高和手术切缘阳性与PMRT使用相关。

核心结论

  • 在迄今评估淋巴结阴性TNBC患者PMRT使用的最大样本研究中,T1和T2期患者PMRT使用率低。
  • pT3期患者接受PMRT观察到OS获益,而其他T分期组未见PMRT获益。
  • 作者建议进一步前瞻性研究以明确PMRT在淋巴结阴性TNBC患者中的获益。

研究设计与样本

  • 查询美国国家癌症数据库(2004-2014年),纳入非转移性TNBC pT1-4N0M0期行乳房切除术的女性患者。
  • 采用多因素logistic回归分析PMRT使用的相关因素。
  • 采用Kaplan-Meier分析按pT分期分层评估PMRT与观察组的总生存(OS)。
  • 采用Cox比例风险模型确定与OS相关的变量。

主要发现

  • 共14,464例患者符合入选标准,其中1,569例(10.8%)接受PMRT,12,895例(89.2%)未接受PMRT。
  • PMRT使用随pT分期显著变化,T1期患者仅5.7%接受PMRT,而T3期患者51.6%接受PMRT。
  • PMRT与pT3期患者更优OS相关,但在其他T分期患者中未见获益。
  • 年龄较大与PMRT使用可能性降低相关,T分期升高和手术切缘阳性与PMRT使用相关。
  • 多因素分析显示,年龄较大、T分期升高和手术切缘阳性与更差OS相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者建议进一步前瞻性研究以明确PMRT在淋巴结阴性TNBC患者中的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The use of post-mastectomy radiation therapy (PMRT) for patients with node-negative, triple negative breast cancer (TNBC) is controversial. This study of a large, contemporary US database described national practice patterns and addressed the impact of PMRT on survival for patients with node-negative TNBC. METHODS: The National Cancer Data Base was queried (2004-2014) for women with non-metastatic TNBC with pT1-4N0M0 disease undergoing mastectomy. Use of PMRT was assessed. Multivariable logistic regression ascertained factors associated with PMRT use. The Kaplan-Meier analysis evaluated overall survival (OS) between patients managed with either PMRT or observation following mastectomy when stratifying by pT stage. Cox proportional hazards modeling determined variables associated with OS. RESULTS: A total of 14,464 patients met the selection criteria; of these, 1,569 (10.8%) received PMRT, whereas 12,895 (89.2%) did not receive PMRT. Use of PMRT varied significantly with pT stage, with only 5.7% of T1 patients undergoing PMRT, while 51.6% of patients with T3 disease underwent PMRT. Use of PMRT was associated with superior OS for patients with pT3 disease but not for patients with other T stages. Greater age was associated with decreased likelihood of PMRT use, while increased T stage and positive surgical margins were associated with use of PMRT. On multivariate analysis, increased age, T stage, and positive surgical margins were associated with worse OS. CONCLUSIONS: In the largest study to date evaluating the use of PMRT in patients with node-negative TNBC, the use of PMRT was low in patients with T1 and T2 disease. Additionally, while an OS benefit was observed with the use of PMRT in patients with T3 disease, there was no benefit with the use of PMRT in other T stage groups. Further prospective studies are recommended to further elucidate the benefit on PMRT in patients with node-negative TNBC.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Haque W, Verma V, Farach A, et al. Postmastectomy radiation therapy for triple negative, node-negative breast cancer. Radiother Oncol. 2018. PMID: 30825969. doi:10.1016/j.radonc.2018.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。